ERBB2 and metastatic neoplasm: The likelihood ratio of developing BM as first site of metastatic disease did not differ significantly between the breast cancer subtypes (luminal subtype 21.7% HER-2 subtype 17.7% triple-negative subtype 20.7% P=0.372, χ2-test).